What is the current stock price of Indaptus Therapeutics, Inc. (INDP)?

As of the latest market data, Indaptus Therapeutics, Inc. (INDP) is trading at $2.11. The stock has seen a gain of 14.05% today.

Does Indaptus Therapeutics, Inc. (INDP) pay a dividend?

Based on current data, Indaptus Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Indaptus Therapeutics, Inc.?

The current market capitalization of Indaptus Therapeutics, Inc. (INDP) is approximately unavailable.

INDP

Indaptus Therapeutics, Inc.·Healthcare

2.11

14.054%(+0.26)

Market Closed

2.40

13.744%(+0.29)

After Hours

Last Updated: — ET

52W L: $1.5152W H: $19.91

INDP NEWS

defenseworld.net

Apr 2

Comparing Indaptus Therapeutics (NASDAQ:INDP) & Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ: ALDX - Get Free Report) and Indaptus Therapeutics (NASDAQ: INDP - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Profitability This table compares Aldeyra Therapeutics and

defenseworld.net

Mar 5

Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday

Indaptus Therapeutics (NASDAQ: INDP - Get Free Report) is expected to be issuing its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($4.36) per share for the quarter. Indaptus Therapeutics Stock Up 6.9% INDP opened at $2.01 on Thursday. The firm has a market cap of $4.50

Company Profile

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2015-08-04

Beta

0.99

Websiteindaptusrx.com↗